HOME >> BIOLOGY >> NEWS
Study produces conflicting findings on the use of anti-anemia drug in cancer patients

LOS ANGELES Results from a phase III drug trial indicate that an anti-anemia drug did not significantly decrease the need for blood transfusions in patients not on chemotherapy, and decreased overall patient survival when compared to placebo, according to researchers from the UCLA Medical Center at the 2007 Annual Meeting of the American Association for Cancer Research.

The drug, darbepoetin alfa (DA) is a synthetic form of erythropoietin, a hormone that signals the formation of new red blood cells from within the bone marrow. DA is commonly used as a means of combating anemia in cancer patients who are also receiving chemotherapy. Anemia in cancer patients can result from either chemotherapy or the cancer itself, and it has a measurable effect on quality of life and overall cancer survival.

While some cancer patients not undergoing chemotherapy are also given DA, previous placebo-controlled studies did not show that darbepoetin significantly reduced transfusion risk.

"While the study was not specifically designed to study survival rates, our results indicate a statistically significant decrease in patients given the drug versus those who were given placebo," said John Glaspy, M.D., professor at the University of California, Los Angeles School of Medicine. "Since erythropoietic agents are sometimes used in the U. S. to treat anemia and reduce transfusion risk in patients not on chemotherapy, these results are of concern to the research and clinical cancer communities."

The trial was designed to examine the ability of darbepoetin to reduce the need for blood transfusions in patients with active cancer not undergoing chemotherapy. The trial, held in clinical sites throughout North America, Europe and Australia was supported by the drug's manufacturer, Amgen.

Approximately 1,000 people were enrolled in the study, which was open to patients with most forms of cancer, except myeloid or acute leukemia and Burkitt'
'"/>

Contact: Staci Vernick Goldberg
goldberg@aacr.org
267-646-0616
American Association for Cancer Research
16-Apr-2007


Page: 1 2 3

Related biology news :

1. Study begins to reveal clues to the cause and progression of sepsis
2. Study finds gender differences in renal and other genes contributing to blood pressure
3. Study suggests estrogen deficiency can lead to obesity-induced high blood pressure after menopause
4. Study: Sticking to the sand might not be such good, clean fun for beachgoers
5. Study points to new way to predict death risk from torn aorta
6. Study identifies new gene therapy tools for inherited blindness
7. Study finds contaminated water reaching Floridas offshore keys
8. Study sheds light on why humans walk on two legs
9. Study explains how pathogens evolve to escape detection
10. Study finds hereditary link to premenstrual depression
11. Study identifies energy efficiency as reason for evolution of upright walking

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/14/2019)... ... January 14, 2019 , ... CellMax Life , a ... blood, will present new findings at the ASCO Gastrointestinal Cancer Symposium in San ... results from this study show CellMax Life’s blood test, based on its proprietary ...
(Date:1/10/2019)... ... 2019 , ... Dr. Beanlands is the Vered Chair and Division Head of ... is also Director of its National Cardiac PET Centre, and Professor in the University's ... in the Department of Cellular and Molecular medicine. , He is a founding member ...
(Date:1/10/2019)... ... January 10, 2019 , ... A major goal for ... vitro studies and significantly more expensive in vivo studies in order to reduce ... address this need, researchers have begun to adopt 3D cell culture models which ...
Breaking Biology News(10 mins):
(Date:1/30/2019)... ... January 29, 2019 , ... Actus Therapeutics, a ... of the first patient in a phase 1/2 clinical study of ACTUS-101 in ... high morbidity and often leads to premature death. There are variable rates ...
(Date:1/30/2019)... VERONA, Italy (PRWEB) , ... January 30, 2019 ... ... Without Walls section of the international tasting 5StarWines to promote and give recognition ... sulfite wines. The Wine Without Walls selection takes place in Verona, Italy, contemporaneously ...
(Date:1/24/2019)... ... January 23, 2019 , ... ... has awarded microbiome research support in study design, planning, sample collection, and analysis ... Sciences, St. Augustine Campus in Trinidad led by Dr. Elaine Monica Davis, MBBS, ...
(Date:1/20/2019)... ... January 17, 2019 , ... Today, Advanced Solutions, ... of a specialized automation technology, titled Automate 3D. Automate 3D, produced by Advanced ... and drawings to deliver to end-users, customers, and ERP systems. , ...
Breaking Biology Technology:
Cached News: